Search

Search Results

• 

  PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi¹, S. Bolognini^1|2, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.512

  96

  PDF: 32
• 

  PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti^1|2|3, P. Gomez-Rosas^1|4|5, S. Bolognini¹, C. Ticozzi¹, D. Romeo¹, F. Schieppati^1|3, L. Barcella^1|3, F. Petrelli⁶, A. D'Alessio⁷, R. Labianca⁷, A. Falanga^1|2|3 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; ³ERN EuroBloodNet; ⁴Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; ⁵Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁶Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; ⁷Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.538

  94

  PDF: 22
• 

  PO43 | ELEVATED CIRCULATING TISSUE PLASMINOGEN ACTIVATOR LEVELS PREDICT GASTROINTESTINAL AND BREAST CANCER RISK: A PROSPECTIVE NESTED CASE-COHORT STUDY S. Bolognini^1|2, C. Ticozzi¹, P. Gomez-Rosas^1|3, F. Schieppati^1|2, G. Sampietro⁴, L. Barcella¹, M. Marchetti^1|2, A. Falanga^1|2 | ¹Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; ²School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; ³Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; ⁴Unit of Epidemiology and Statistics, ATS Bergamo, Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.537

  118

  PDF: 33
• 

  PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas^1|2|, D. Romeo¹, S. Bolognini¹, C. Ticozzi¹, F. Schieppati¹, A. D’Alessio⁴, R. Labianca⁴, A. Falanga^1|5|6, M. Marchetti^1|5|6 | ¹Hospital Papa Giovanni XXIII, Bergamo, Italy; ²Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; ³Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; ⁴Fondazione ARTET Onlus, Bergamo, Italy; ⁵ERN EuroBloodNet; ⁶School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.536

  100

  PDF: 26